Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart valve study halted early: which blood thinner is safer?

NCT ID NCT02817789

Terminated Disease control Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compared two antiplatelet drug regimens after transcatheter aortic valve implantation (TAVI) for aortic stenosis. One group received ticagrelor alone, the other received aspirin plus clopidogrel. The goal was to see which caused fewer serious complications like bleeding, stroke, or kidney injury. However, the trial was terminated early after enrolling only 50 of the planned 308 participants, so no firm conclusions can be drawn.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Ticagrelor (antiplatelet drug) compared to a combination of lysine acetylsalicylate (aspirin) and clopidogrel (antiplatelet drug)
What this could lead to
If successful, this could identify a safer antiplatelet regimen after TAVI, reducing bleeding and stroke risks.
What could go wrong
The trial was terminated early with only 50 participants, so results are very limited. It is unclear if ticagrelor alone is truly safer or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AORTIC VALVE STENOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aortic valve stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AORTIC VALVE STENOSIS

Contacts and locations

Locations

  • APHM

    Marseille, 13005, France

  • APHP

    Paris, 75013, France

  • CHRU de Lille

    Lille, 59037, France

  • CHRU de Nîmes

    Nîmes, 30029, France

  • CHU de Bordeaux

    Pessac, 33604, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.